introduction Doxorubicin-based chemotherapy has been and it is yet currently the cornerstone of the breast cancer chemotherapy treatment. Cardiotoxicity is a well-known doxorubicinassociated dose-limiting toxicity (DLT) and, as a consequence of this, it is an important concern in the breast cancer chemotherapy treatment. Moreover, doxorubicin-associated cardiotoxicity may be unpredictable because it can appear at lower doses than expected in patients with a genetic predisposition as it has been demonstrated in patients carrying selected polymorphisms of the NAD(P)H oxidase and doxorubicin efflux transporters [1] . In addition, most breast cancer patients will receive radiation treatment on the chest wall which is a well-known risk factor for doxorubicinassociated cardiotoxicity, mainly if the cancer is located in the left breast. Liposomal formulations of doxorubicin have been developed with the aim to decrease cardiotoxicity [2] . Liposome-encapsulated doxorubicin citrate (LD) (TLC D-99, Myocetä; Cephalon Inc., Frazer, PA) a nonpegylated liposome formulation of doxorubicin has been shown to offer a significant decrease in the cardiotoxicity when compared with doxorubicin while preserving doxorubicin-associated antitumor efficacy in the treatment of metastatic breast cancer patients [3] [4] [5] [6] . Docetaxel is a member of the taxanes, a family of chemotherapy drugs which promote tubulin assembly into microtubules and inhibits their depolymerization. Docetaxel is used in both, metastatic and adjuvant setting in association with doxorubicin, improving the results of doxorubicin-based chemotherapy. Both anthracyclines and taxanes administered as single agents represent the most active groups of cytotoxic agents for the treatment of breast cancer. Up to 15%-20% of women diagnosed with early breast cancer have tumors that are HER-2 positive which is associated with a high risk of relapse and death from metastatic disease [7] [8] [9] [10] [11] [12] . Trastuzumab, a recombinant humanized mAb, directed against the extracellular domain of the HER-2, has shown to increase overall survival in HER-2-overexpressing breast cancer when associated with chemotherapy, as compared with chemotherapy alone. This improvement has been demonstrated in both settings, patients undergoing palliative chemotherapy [13] [14] [15] as well as in patients undergoing adjuvant chemotherapy [16, 17] . However, cardiotoxicity is one of the main adverse events which have been observed with trastuzumab use. Thus, the combination of trastuzumab and conventional anthracyclines has shown to carry a significant risk of cardiotoxicity [8] [9] [10] [18] [19] [20] [21] [22] .
Neo-adjuvant chemotherapy emerged as a successful strategy to treat extensive tumors that were not candidates for surgery. This procedure was shown to be effective in prolonging overall survival [23] . As a consequence of this, neo-adjuvant treatment is being used to treat not only locally advanced breast cancer but also large, less advanced tumors. These large tumors, when treated with a neo-adjuvant approach, are optimal to evaluate efficacy of new drugs and combinations because the tumor is easily measurable and, thus, the response may be easily determined. Moreover, biologic studies can be carried out in tumor samples obtained before and after chemotherapy treatment.
We herein report the results of a phase I clinical trial attempting to establish the maximum tolerated dose (MTD) as well as the DLT of the combination of LD with docetaxel and trastuzumab, with pegfilgrastim support, as a neo-adjuvant treatment for women with HER-2-overexpressing stages II and IIIA breast cancer, paying special attention to cardiotoxicity.
patients and methods

patient population
Patients were enrolled in this trial from April 2004 to March 2006 in six centers in Spain. The inclusion criteria the patients eligible had to meet were histologically proven (breast core biopsy) stages II and IIIA breast cancer-overexpressing HER-2, confirmed by FISH carried out at a central reference laboratory; absence of systemic disease measured by bilateral mammogram, chest X-ray, abdominal computed tomography scan or ultrasound, and bone scintigraphy; a Karnofsky performance status of 80 or higher; hemoglobin ‡10 g/dl, absolute neutrophil count ‡2 · 10 9 /l, and platelet count ‡100 · 10 9 /l; adequate hepatic and renal functions; left ventricular ejection fraction (LVEF) ‡50%; no previous chemotherapy treatment (including anthracyclines or taxanes) for any previous malignancy; and no previous radiotherapy treatment for breast cancer; all patients were females at least 18 years of age considered to be fit to receive combination chemotherapy. Patients with bilateral invasive breast cancer or preexisting motor or sensorial neurotoxicity grade ‡2 on the basis of the National Cancer Institute-Common Toxicity Criteria version 2.0 (NCI-CTC v2.0) score system were excluded. Patients were required to provide written informed consent before inclusion in the study. The study protocol was approved by the institutional review board of each participating institution and was conducted according to the principles of the Declaration of Helsinki and the applicable guidelines for Good Clinical Practice.
drugs administration
All administered drugs were supplied by the corresponding pharmaceutical companies (LD by Cephalon, docetaxel by Sanofi-Aventis, trastuzumab by Roche and pegfilgrastim by Amgen). Both the LD and docetaxel were administered as a 60-min i.v. infusion, escalated dose, on day 1 every 21 days. Trastuzumab was administered at fixed doses of 4 mg/kg loading dose on day 1, followed by 2 mg/kg weekly. Pegfilgrastim was administered at 6 mg, s.c., on day 2, once per cycle. It was planned to administer until a maximum of six treatment cycles, once every 21 days. The initial dosing regimen for the LD and docetaxel combination was chosen on the basis of previous studies [24, 25] .
study design
The whole plan of treatment consisted of six cycles of therapy in responding patients who achieve clinical and radiological complete response, partial response or stable disease after three cycles, according to the study protocol, after which breast surgery is carried out. The starting dose of LD and docetaxel was 60 and 75 mg/m 2 , respectively (dose level 0). Escalated dose of LD and docetaxel planning is shown in Table 1 . DLT was defined as the occurrence in the first two cycles of any of the following events: any hematological toxicity, causing >7 days delay of a subsequent cycle; febrile neutropenia; thrombopenia grades 3-4 associated with hemorrhage; and any grades 3-4 non-hematological toxicity, except nausea, vomiting and alopecia. Cohorts of three patients each were included at each dose level. If no DLT was observed in a level, an additional cohort of three patients was included in the following dose level. If any DLT was observed in one of three patients in one dose level, an additional cohort of three patients was included at the same dose level. If two or three out of three patients or two or more out of six patients at the same dose level experienced any DLT, it was considered that the MTD had been reached and the dose level right below was considered to be the MTD. Toxic effects were graded following the NCI-CTC v2.0. Although the study was not designed for such a purpose, a description of the efficacy results in terms of response rate was preplanned. Clinical and radiological responses were evaluated according to the Response Evaluation Criteria in Solid Tumors [26] . Pathological response was assessed following the Miller and Payne system, a five-point histologically grading method, which quantifies the reduction in tumor cellularity, compared with the pre-treatment tumor core biopsy [27] .
results
A total of 20 patients were enrolled in this study. Two patients were removed from the study. The first patient, at 22 level (LD 50/Doc 70), experienced a chronic hepatitis C reactivation after cycle 1 and she was withdrawn from the study. The second one was enrolled in the study but she never received the treatment due to internal problems with the Hospital Pharmacy Department. A total of 18 patients were assessable for toxicity as well as for efficacy. Demographic patient characteristics are listed in Table 2 . Annals of Oncology original article diarrhea in one patient and a combination of grade 3 diarrhea and grade 3 stomatitis in another patient), a deescalated dose drug administration was carried out instead of the escalated one that had been initially planned. Deescalated dose of LD and docetaxel, actually carried out, is shown in Table 3 . Diarrhea and febrile neutropenia were the most commonly observed toxic effects at the first dose levels and were the main DLT. All the DLTs are listed in Table 4 . At the MTD, there were no episodes of DLT. A total of three patients [two in level 0 and one in 21 level (LD 55/Doc 75)] experienced nonhematological toxicity that resulted in dose reduction during cycle 1. A total of three patients [one in 22 level and two in 23 level (LD 50/Doc 65)] experienced non-hematological toxicity that resulted in dose reduction during cycle 2. Four patients had treatment delays. The first patient due to grade 2 liver function test abnormalities, the second patient due to grade 2 rash, the third patient due to infection without neutropenia associated with grade 2 rash, and the fourth patient due to arthralgias associated with epigastric pain. One additional patient missed days 8 and 15 trastuzumab treatment secondary to grade 2 diarrhea, fatigue, myalgia, urinary infection, abdominal pain, and cephalalgia.
One patient developed grade 3 infection without neutropenia (an episode of pneumonia due to Klebsiella pneumoniae). Grade 3-4 toxic effects of all the cycles of treatment are listed in Table 5 . Overall, six patients did not complete treatment secondary to toxicity. 
efficacy
A total of 18 patients were assessable for response. Evaluation of response has been carried out after three and six cycles of treatment. All patients underwent surgery after neo-adjuvant treatment. A clinical response has been obtained in 14 patients (78%), eight of which (44%) with a clinical complete response. A radiological response has been obtained in 13 patients (72%) including eight radiological complete responses (44%). In 14 patients (78%), conservative surgery was carried out and four patients (22%) underwent a mastectomy. Margins of resection were negative in all cases and seven patients had positive lymph nodes, including one patient with five affected nodes. Pathological response was evaluated according to the Miller and Payne system. A complete disappearance of breast cancer cellular elements in the resected specimen was observed in eight patients (44%). Pathological complete response (pCR) in both breast and axillary lymph nodes was achieved in six patients (33%).
discussion
This phase I trial is the first study reported of a regimen combining LD, docetaxel, and trastuzumab in breast cancer patients. This regimen has been administered within a dose-intense regimen which needed the prophylactic use of pegfilgrastim because a rate of febrile neutropenia >20% was expected.
In our study, the starting dose level (LD 60 mg/m 2 and docetaxel 75 mg/m 2 , dose level 0) has proved to be too toxic, resulting in two of three patients experiencing a DLT (grade 3 diarrhea in one patient and a combination of grade 3 diarrhea and grade 3 stomatitis in another patient). Thus, deescalation of the dose in the subsequent cohorts had to be carried out instead of the planned classical phase I escalation method. An unexpected high rate of grade 3 diarrhea has been observed (another patient in the 23 level has experienced it). Diarrhea is not dose limiting for either LD or docetaxel when used as LVEF, left ventricular ejection fraction; NOS, Not otherwise specified; ER, estrogen receptor; PR, progesterone receptor. The results on cardiotoxicity should be highlighted. Only one patient experienced grade 2 decline of the LVEF (at 21 level). At this level, LD has been administered at 55 mg/m 2 , 5 mg/m 2 higher than the dose at MTD. In addition, six more patients experienced grade 1 LVEF decline. All the patients experiencing these cardiac events remained asymptomatic and thus no cases of clinical congestive heart failure have been observed. In addition, no cases of early drop out from the study because of cardiotoxicity have been observed, either. These results are important for a combination of an anthracycline with trastuzumab, a well-known cardiotoxic combination. In addition, many, if not all, of these patients will continue to receive additional trastuzumab treatment. However, due to the small sample size of our study, we consider that cardiotoxicity results should be confirmed in future trials, such as a phase II trial we are now conducting. Changing conventional doxorubicin for another less cardiotoxic anthracyline in an anthracycline-taxanetrastuzumab regimen in the neo-adjuvant treatment of breast cancer is a strategy which has previously been reported with mixed results. In a phase II trial, epirubicin was used associated with docetaxel and trastuzumab, showing an exceeding rate of cardiotoxicity for this combination which led to stop the enrollment of patients in the trial [28] . Trastuzumab, paclitaxel, and epirubicin in combination have recently been evaluated in the neo-adjuvant setting [29] . Despite the small sample size of this trial, its results indicated that the addition of trastuzumab to chemotherapy significantly increased pCR rates without incurring the risk of clinical congestive heart failure. The first data on the association of LD and trastuzumab were presented at the ASCO meeting in 2002. In this phase I-II study, patients with metastatic breast cancer which had previously been treated with anthracyclines received treatment with LD and trastuzumab. Along with a global response rate of 58%, the key finding of the trial was the excellent cardiac tolerability: only two patients experienced a reversible decline in the LVEF [30] . The results of a recent phase II study which investigated the combination of LD with weekly trastuzumab and paclitaxel in patients with HER2-positive locally advanced or metastatic breast cancer reported high response rates in both groups of patients (100% and 96% respectively), with acceptable toxicity and no association with symptomatic cardiac heart failure [31] .
Results on efficacy should be considered only as exploratory. Breast cancer patients who achieve a pCR after neo-adjuvant chemotherapy have an increased overall survival as compared with the patients who did not [32] . We consider that the rate of pCR in our study, with 33% of patients having a pCR in both breast and axillary lymph nodes, is promising and warrants further investigation.
In conclusion, we have demonstrated that the MTD and recommended doses for phase II trials of LD and docetaxel in combination when administered with prophylactic pegfilgrastim and standard dose trastuzumab are LD 50 mg/m 
